219 related articles for article (PubMed ID: 28375573)
1. Delayed TSH recovery after dose adjustment during TSH-suppressive levothyroxine therapy of thyroid cancer.
Kim HI; Kim TH; Kim H; Kim YN; Jang HW; Kim JH; Hur KY; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2017 Sep; 87(3):286-291. PubMed ID: 28375573
[TBL] [Abstract][Full Text] [Related]
2. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
3. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy.
Verburg FA; Smit JW; Grelle I; Visser TJ; Peeters RP; Reiners C
Clin Endocrinol (Oxf); 2012 Apr; 76(4):577-81. PubMed ID: 22017394
[TBL] [Abstract][Full Text] [Related]
4. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients.
Yavuz DG; Yazan CD; Hekimsoy Z; Aydin K; Gokkaya N; Ersoy C; Akalın A; Topaloglu O; Aydogan BI; Dilekci ENA; Alphan Uc Z; Cansu GB; Ozsari L; Iyidir OT; Olgun ME; Keskin L; Mert M; Can B; Gungor K; Galip T; Cantürk Z; Elbuken G; Pekkolay Z; Kutbay NO; Yorulmaz G; Kalkan AT; Unsal YA; Yay A; Karagun B; Bozkur E
Clin Endocrinol (Oxf); 2022 Dec; 97(6):833-840. PubMed ID: 35639050
[TBL] [Abstract][Full Text] [Related]
5. Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments.
Grani G; Tumino D; Ramundo V; Ciotti L; Lomonaco C; Armillotta M; Falcone R; Lucia P; Maranghi M; Filetti S; Durante C
J Endocrinol Invest; 2019 Dec; 42(12):1485-1490. PubMed ID: 31203497
[TBL] [Abstract][Full Text] [Related]
6. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer.
Altuntaş SÇ; Hocaoğlu Ç
Horm Metab Res; 2021 Oct; 53(10):683-691. PubMed ID: 34607367
[TBL] [Abstract][Full Text] [Related]
7. Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine Medication.
Kim HI; Kim TH; Kim H; Kim YN; Jang HW; Chung JH; Moon SM; Jhun BW; Lee H; Koh WJ; Kim SW
PLoS One; 2017; 12(1):e0169775. PubMed ID: 28081173
[TBL] [Abstract][Full Text] [Related]
8. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
9. The thyroid axis 'setpoints' are significantly altered after long-term suppressive LT4 therapy.
Verburg FA; Mäder U; Grelle I; Visser TJ; Peeters RP; Smit JW; Reiners C
Horm Metab Res; 2014 Oct; 46(11):794-9. PubMed ID: 24867137
[TBL] [Abstract][Full Text] [Related]
10. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
11. The relationship of preconception thyrotropin levels to requirements for increasing the levothyroxine dose during pregnancy in women with primary hypothyroidism.
Abalovich M; Alcaraz G; Kleiman-Rubinsztein J; Pavlove MM; Cornelio C; Levalle O; Gutierrez S
Thyroid; 2010 Oct; 20(10):1175-8. PubMed ID: 20860419
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer.
Schumm MA; Lechner MG; Shu ML; Ochoa JE; Kim J; Tseng CH; Leung AM; Yeh MW
Endocr Pract; 2021 Jul; 27(7):691-697. PubMed ID: 33642257
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
14. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
15. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism.
Sachmechi I; Reich DM; Aninyei M; Wibowo F; Gupta G; Kim PJ
Endocr Pract; 2007; 13(4):345-9. PubMed ID: 17669709
[TBL] [Abstract][Full Text] [Related]
16. Effect of thyrotropin suppressive therapy on heart rate variability and QT dispersion in patients with differentiated thyroid cancer.
Liu C; Lv H; Li Q; Fu S; Tan J; Wang C; Wang X; Ma Y
Medicine (Baltimore); 2020 Jul; 99(28):e21190. PubMed ID: 32664162
[TBL] [Abstract][Full Text] [Related]
17. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
18. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Do Cao C; Wémeau JL
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
[TBL] [Abstract][Full Text] [Related]
19. Adequate levothyroxine doses for the treatment of hypothyroidism newly discovered during pregnancy.
Abalovich M; Vázquez A; Alcaraz G; Kitaigrodsky A; Szuman G; Calabrese C; Astarita G; Frydman M; Gutiérrez S
Thyroid; 2013 Nov; 23(11):1479-83. PubMed ID: 23731335
[TBL] [Abstract][Full Text] [Related]
20. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer.
Burmeister LA; Goumaz MO; Mariash CN; Oppenheimer JH
J Clin Endocrinol Metab; 1992 Aug; 75(2):344-50. PubMed ID: 1639933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
